Generation Bio (GBIO)
GBIO
Gene Therapy
BiotechSign Signal Grade
F
Signal Grade
1.2/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Insider Buying
0
Publications
100
Clinical Activity
0
Pipeline Overview
- Therapeutic Focus
- Gene Therapysrc
Clinical Trial Activity
0
Clinical Trials
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
5
PubMed Publications
0
Catalyst Records
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Recent News & SEC Filings
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Prevalence and related factors of symptom-based sexually transmitted infections among men who inject drugs: findings from three nation-wide surveys in Iran, 2010-2023. — BMJ Open 2026 Sep 22 PMID 42772866
- Self-Oxygenating Microneedle Patches Enabled by Black Phosphorus Nanocomposites for Sequential Photothermal/Photodynamic Melanoma Therapy. — ACS Appl Mater Interfaces 2026 Sep 23 PMID 42771792
- ProST: an image prompt-guided multimodal representation learning framework for spatial domain identification. — Bioinformatics 2026 Sep 22 PMID 42770856
- Deep learning-driven de novo discovery of binders targeting the transmembrane domain of BamA. — Arch Microbiol 2026 Sep 21 PMID 42766017
- Multicentre, 2×2 factorial, randomised, open-label trial of neuromodulators and cough control therapy for refractory or unexplained chronic cough: the FORTITUDE trial protocol. — BMJ Open 2026 Sep 18 PMID 42760069
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Generation Bio.
Full GBIO Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.